Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Science News / Manufacturing error in Oxford-AstraZeneca coronavirus vaccine raises pertinent questions
  • Science

    Manufacturing error in Oxford-AstraZeneca coronavirus vaccine raises pertinent questions

    Shalini Ojha
    Written by
    Shalini Ojha
    Twitter
    Last updated on Nov 27, 2020, 01:54 am
    Manufacturing error in Oxford-AstraZeneca coronavirus vaccine raises pertinent questions
  • After announcing that their coronavirus vaccine candidate was nearly 70% effective, the University of Oxford and its partner, AstraZeneca, on Wednesday admitted to a manufacturing error, which has now sparked important questions about the results.

    Experts have said the pharma giant's conduct has eroded confidence, though the company maintained that the trials "were conducted to the highest standards."

    Here's what happened.

  • In this article
    Lower doses turned out to be more effective Why did lower dose generate a better response? Those who received low doses were not above 55 The composite result doesn't represent either doses: Expert Now, regulators will thoroughly judge the trial results AstraZeneca's shares fell about 5 percent this week
  • What happened

    Lower doses turned out to be more effective

    Lower doses turned out to be more effective
  • The error concerns vaccine dosage received by some volunteers — AstraZeneca failed to explain why some participants didn't get the desired doses.

    When the results of the large-scale trial were out, it was learned that in cases of smaller doses, the vaccine was 90% effective. In larger doses, the efficacy was reduced to 62%.

    Thereafter, the developers said the vaccine was approximately 70% effective.

  • Questions

    Why did lower dose generate a better response?

    Why did lower dose generate a better response?
  • The most important questions were linked to the massive difference between the efficiencies of both doses, and better results that the lower dose generated. Oxford and AstraZeneca didn't explain why this happened.

    The fact that two differently-designed trials in Brazil and Britain were used to arrive at the conclusion, didn't help either.

    Adding to the confusion, Oxford admitted some vials didn't have the right concentration.

  • Details

    Those who received low doses were not above 55

  • Moreover, only 2,741 people received the half dose followed by the full dose, as compared to 8,895 getting full doses twice. This, experts believe, makes it difficult to ascertain if the efficacy is real.

    Those in the low-dose category were aged under 55, meaning they have a stronger immune response.

    This could become a problem when AstraZeneca applies for emergency use approval.

  • Quote

    The composite result doesn't represent either doses: Expert

  • On the findings, former director of immunization at UK Department of Health, David Salisbury, said, "You've taken two studies for which different doses were used and come up with a composite that doesn't represent either of the doses. I think many people are having trouble with that.″

  • Future

    Now, regulators will thoroughly judge the trial results

  • Worryingly, the responses from Oxford haven't been helpful.

    Sarah Gilbert, one of the scientists leading the research, said, "It's the Goldilocks amount that you want, I think, not too little and not too much. Too much could give you a poor quality response as well."

    As for the future course of action, the trial results will now be scrutinized by the regulators.

  • Shares

    AstraZeneca's shares fell about 5 percent this week

  • The murky results reflected in the markets as well, with AstraZeneca's shares falling about 5% this week. As compared to its rivals — Pfizer and Moderna — AstraZeneca's results aren't as transparent, which explains the mistrust among investors, reports NYT.

    To note, Pune-based Serum Institute of India has also partnered with the company to produce millions of doses, to help India defeat the pandemic.

  • Pfizer
  • Oxford
  • University of Oxford
  • Coronavirus
  • Moderna
  •  
Latest News
  • Owner of explosives-laden vehicle near Mukesh Ambani's house found dead
    Owner of explosives-laden vehicle near Mukesh Ambani's house found dead
    India
  • CBSE Class X, XII Board exam date-sheet revised
    CBSE Class X, XII Board exam date-sheet revised
    India
  • iOS 14.5 doesn't have a default music service setting
    iOS 14.5 doesn't have a default music service setting
    Science
  • Overseas Citizens need permission for 'Tabligh, journalistic activities': Centre
    Overseas Citizens need permission for 'Tabligh, journalistic activities': Centre
    India
  • Gajendra Chauhan to star in movie inspired by Narendra Modi
    Gajendra Chauhan to star in movie inspired by Narendra Modi
    Entertainment
Related Timelines
  • India set to start COVID-19 vaccination; panel approves Oxford vaccine
    India set to start COVID-19 vaccination; panel approves Oxford vaccine
    India
  • After Pfizer, Oxford-AstraZeneca's COVID-19 vaccine approved in UK
    After Pfizer, Oxford-AstraZeneca's COVID-19 vaccine approved in UK
    World
  • Indian government could approve Oxford-AstraZeneca's coronavirus vaccine by next week
    Indian government could approve Oxford-AstraZeneca's coronavirus vaccine by next week
    India
  • Oxford-AstraZeneca release final-stage trial results, coronavirus vaccine labeled safe
    Oxford-AstraZeneca release final-stage trial results, coronavirus vaccine labeled safe
    Science
Trending Topics
Samsung OnePlus Mobiles Android TV Smart TV Latest Gadget Launch MediaTek Dimensity 1000+ COVAXIN Latest Tech News Upcoming Mobile Phones
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love Science news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Samsung Virat Kohli Rohit Sharma
Cricket News YouTube Hollywood News WhatsApp Bollywood News ISRO Yoga Honda Batman Football News
BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Royal Challengers Bangalore Toyota Fashion Tips Taj Mahal Mercedes
Friends Series Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV Smart TV Marvel Comics Avengers Neha Kakkar Premier League
Big Bang Theory Liverpool Chelsea X-Men
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021